INTRODUCTION
Exome sequencing studies have now identified hundreds of gene mutations carrying an increased risk for neurodevelopmental disorders (Allen et al., 2013; De Rubeis et al., 2014; Iossifov et al., 2014; Deciphering Developmental Disorders Study, 2015) . Of these, mutations in genes encoding chromatin regulators have emerged as a common risk factor, with CHD2, a member of the chromodomain helicase DNA-binding (CHD) family of proteins, being frequently affected (Carvill et al., 2013; Carvill et al., 2015) . CHD2 is an ATP-dependent chromatin-remodeling factor with poorly understood function in the developing or adult brain. In human, CHD2 haploinsufficiency is associated with intellectual disability, a variety of catastrophic childhood epilepsies, autism spectrum disorder, and photosensitivity (Neale et al., 2012; Rauch et al., 2012; Ché nier et al., 2014; Galizia et al., 2015) , with large phenotypic variability among affected individuals. In mice, heterozygous deletion of Chd2 results in histological abnormalities of heart, muscle, lung, liver, kidney, spleen, and bone (Marfella et al., 2006 (Marfella et al., , 2008 Harada et al., 2012; Kulkarni et al., 2008) . Initial studies in brain indicate that Chd2 knockdown during the peak of embryonic neurogenesis promotes production of neurons from neural progenitors, possibly depleting the precursor pool (Shen et al., 2015) . However, unlike other CHD family members in which recent progress using animal models has led to important mechanistic insights about behavioral phenotypes and cellular pathways (Durak et al., 2016; Katayama et al., 2016; Gompers et al., 2017; Platt et al., 2017) , there is essentially nothing known about brain defects that arise as a consequence of Chd2 haploinsufficiency.
Understanding how mutations in chromatin remodeling genes impact brain function may reveal new opportunities for targeted therapies. This led us to generate a Chd2 mutant mouse line and investigate the effect of Chd2 haploinsufficiency on the developing and mature mouse brain. Our findings support the hypothesis that Chd2 has a critical function in forebrain neurogenesis in vivo and the generation of GABAergic interneurons in particular. We also found evidence of a functional role for Chd2 in cortical circuit physiology and long-term spatial memory.
RESULTS

CHD2 Is Expressed in Neurons and Oligodendrocytes
We first determined the expression profile of CHD2 in wild-type (WT) C57BL/6J mice at postnatal day 30 (P30) (n = 6 mice) (E) At P30, western blot analysis showed a reduction of CHD2 protein in brain of Chd2 +/À (p = 0.027, n = 3 mice per genotype). (F) Mean body weight of male and female Chd2 +/À mice was reduced compared to WT littermates (n = 17-23 mice per genotype). (G) Immunostaining for BRN2 (magenta), CTIP2 (green), and DAPI (blue) in somatosensory cortex (left) and hippocampus (right) at P30. (H) Thickness of individual cell layers in somatosensory cortex (SS Ctx) was not altered by Chd2 +/À (n = 4 mice per genotype). (I) Width of granule cell layer (GCL) or CA1 pyramidal cell layer (CA1) was not altered by Chd2 +/À (n = 4 mice per genotype). Error bars, SEM; *p < 0.05; **p < 0.01; scale bars, 75 mm in (A) and 150 mm in (G) . See also Figure S1.
( Figure 1) . Immunofluorescence experiments revealed CHD2 was widely expressed throughout the young adult mouse brain, with especially strong expression in olfactory bulb, neocortex, hippocampus, and cerebellum (Figures S1A and S1B). These observations are consistent with RNA expression patterns of Chd2 detected by in situ hybridization (Gene Paint; https://gp3.mpg.de/results/chd2). To determine whether CHD2 expression was limited to a specific brain cell type, we further evaluated coronal sections from hippocampus of P30 WT mice (n = 11 mice). We found that CHD2 co-localized in nearly all mature neurons (NEUN-positive, 99.8% ± 0.1%), GABAergic interneurons (GAD67-positive, 97.7% ± 0.39%), and oligodendrocytes (OLIG2-positive, 97.6% ± 0.95%). Conversely, CHD2 was not expressed in the majority of GFAP-positive astrocytes (0.4% ± 0.4%) ( Figures 1A and 1B) . CHD2 co-localized with DAPI, consistent with its role in chromatin regulation ( Figure S1C ).
Generation of Chd2 +/-Mice In humans, CHD2 mutations are typically loss of function (Carvill et al., 2015) . To establish a mouse line with a heterozygous lossof-function mutation in Chd2 (i.e., Chd2 +/À mice), we crossed transgenic mice containing loxP-flanked exon 3 of Chd2 (i.e., Chd2 tm1c(EUCOMM)Hmgu mice) with a b-actin Cre line ( Figure 1C ; Figures S1D-S1F). Mice with heterozygous deletion in Chd2 showed approximately half the expression of CHD2 protein in brain as compared to WT littermates (Figures 1D and 1E) . Chd2 +/À mice of both sexes were viable and fertile but had reduced body weight compared to WT littermates (Male: WT: 18.5 ± 0.8 g, n = 17 mice, Chd2 +/À : 16.2 ± 0.9 g, n = 23 mice; two-tailed t test; p = 0.001; Female: WT: 16.4 ± 0.4 g, n = 22 mice, Chd2 +/À : 14.2 ± 0.7 g, n = 22 mice; two-tailed t test; p = 0.0004) ( Figure 1F ). Chd2 +/À mice also exhibited mild lordokyphosis by 2 months of age ( Figure S1H ). This phenotype was not apparent in WT littermates and is consistent with reports of scoliosis in humans with Chd2 mutations (Ché nier et al., 2014; Kulkarni et al., 2008) .
We first asked whether a reduction in Chd2 disrupts cytoarchitecture of the cortex. Analysis of the layer-specific markers BRN2 (layer II/III), CTIP2 (layer V and VI), and DAPI revealed no gross alterations to lamination at P30 ( Figures 1G-1I ), and analysis of NEUN immunostaining showed no obvious laminar disorganization in somatosensory cortex or hippocampus ( Figure S1I ). No significant differences were detected in the thickness of somatosensory neocortex or dorsal hippocampus between genotypes ( Figure 1H ; Figure S1J ). Likewise, we did not observe any differences in the width of the granule cell or CA1 pyramidal cell layers within hippocampus of Chd2 +/À mice compared to WT littermates ( Figure 1I ; Figure S1K ). Finally, we evaluated WT and Chd2 +/À mice for cellular phenotypes of epilepsy in dentate gyrus. Analysis of Timm's staining revealed no mossy fiber sprouting into the inner molecular layer of the dentate gyrus (Mann-Whitney rank-sum test, p = 1.00, U-statistic = 162.00) ( Figure S1L ). We also found no change in the intensity of GFAP immunostaining or density of GFAP+ cells between genotypes (Figures S1M-S1P). Hence, our results show Chd2 haploinsufficiency does not substantially disrupt cortical cytoarchitecture.
Reduced Numbers of GABAergic Interneurons in
Chd2 +/-Mice Because CHD2 was co-expressed with nearly all GABAergic interneurons, we asked whether numbers of individual GABA cell populations were altered in Chd2 +/À mice. At P30, we found $20% decrease in the density of GAD67-expressing cells in somatosensory cortex (WT: 302.3 ± 12.2 GAD67+ cells/mm 2 , Chd2 +/À : 239.8 ± 11.3 GAD67+ cells/mm 2 ; n = 6 mice per genotype, p = 0.03) and hippocampus CA1 (WT: 175.6 ± 5.9 GAD67+ cells/mm 2 , n = 5 mice; Chd2 +/À : 140.8 ± 2.8 GAD67+ cells/mm 2 , n = 6 mice; p = 0.0003) ( Figure 2 ). We also found $10% decrease in the density of NEUN+/GAD67À cells (putative excitatory neurons) in somatosensory cortex (WT: 1,938 ± 45 cells/mm 2 , Chd2 +/À : 1,791 ± 17 cells/mm 2 ; n = 4 mice per genotype, p = 0.03) ( Figure S2 ), suggesting that Chd2 +/À does not selectively alter interneuron number, but no change was found in hippocampus CA1 (WT: 4,235 ± 205 cells/mm 2 , Chd2 +/À : 4,534 ± 192 cells/mm 2 ; n = 4 mice per genotype, p = 0.3). Immunostaining analysis for GABAergic subtypes revealed decreased density of cells expressing parvalbumin (PV; 15% decrease in somatosensory cortex and 22% in CA1), somatostatin (SST; 11% decrease in somatosensory cortex and 31% in CA1), and reelin (12% decrease in CA1) ( Figure 2 ). The density of cells expressing calretinin (CR) or vasoactive intestinal peptide (VIP) was not significantly different between genotypes.
One hypothesis that could explain fewer GABA neurons in Chd2 +/À mutants is that Chd2 +/À may favor the production of oligodendrocytes over interneurons, which derive from the same progenitor regions of the ventral telencephalon (Petryniak et al., 2007) . To test this, we quantified the number of OLIG2+ cells at P30. However, we found no difference in OLIG2+ cell densities in somatosensory cortex (WT: 659.2 ± 33.5 cells/ mm 2 ; Chd2 +/À : 662.7 ± 26.1 cells/mm 2 ; n = 4 mice per genotype; p = 0.94) or hippocampus CA1 (WT: 522.8 ± 10.5 cells/mm 2 , n = 4 mice; Chd2 +/À : 513.8 ± 25.0 cells/mm 2 , n = 3 mice; p = 0.45) ( Figure S3 ). Thus, decreases in interneuron density are unlikely due to increases in oligodendrogenesis in Chd2 +/À mice.
Chd2 +/-Disrupts Cell Proliferation in the Developing Forebrain
Interneuron density in the adult nervous system is largely determined by the size of the precursor pool in the embryo (Southwell et al., 2012) . To investigate whether Chd2 has a role in GABAergic neurogenesis, we crossed Chd2 +/À mice with a GAD67-GFP knockin reporter labeling nearly all GABAergic interneurons (Tamamaki et al., 2003) . CHD2 expression was observed throughout the embryonic brain of WT mice at embryonic day 14.5 (E14.5; n = 12 mice) ( Figures 3A-3C ). In dorsal telencephalon, and in agreement with a previous report (Shen et al., 2015) , CHD2 was expressed at the highest levels in the cortical plate, where it co-localized with the majority of TBR1+ cells, as well as the ventricular zone (VZ) and subventricular zone (SVZ), where CHD2 co-localized with KI67+ mitotically active precursors and PAX6+ radial glia ( Figure 3A Figure S4 ). At this stage, CHD2 strongly co-localized with KI67 and NKX2.1 but only partially co-localized with GAD67-GFP+ cells in MGE. CHD2 was not detected in tangentially migrating interneurons in neocortex ( Figure 3A ). By demonstrating progenitor domain-specific expression of CHD2 during cortical development, our results suggest that CHD2 plays a role in cell proliferation, terminal differentiation, and maturation of cortical principal neurons and GABAergic interneurons.
To determine whether forebrain precursors were altered by Chd2 +/À , we performed a series of immunostaining studies at E14.5. In cortex, we found $35% decrease in the density of KI67-expressing cells in VZ/SVZ of Chd2 +/À mice (WT: 8,087.5 ± 934.8 cells/mm 2 , n = 4 mice; Chd2 +/À : 5,150 ± 180.3 cells/mm 2 ; n = 3 mice; p = 0.04) ( Figures 3D and 3E ). In MGE, we also observed an $35% decrease in the density of KI67-expressing cells in VZ/SVZ of Chd2 +/À mice (WT: 8,910.5 ± 279.5 cells/mm 2 , n = 5 mice; Chd2 +/À : 7,108.3 ± 361.2 cells/mm 2 ; n = 3 mice; p = 0.04). Further analysis at E14.5 revealed a subsequent decrease in NKX2.1-expressing progenitors in MGE (WT: 17,929.2 ± 717.2 cells/mm 2 , n = 6 mice; Chd2 +/À : 15,000 ± 365.5 cells/ mm 2 , n = 5 mice; p = 0.008) and reduced density of GAD67-GFP+ neurons in cortex of Chd2 +/À mice, as compared to WT littermates (WT: 3,122.5 ± 162.9 cells/mm 2 , n = 4 mice; Chd2 +/À : 2,450.5 ± 39.9 cells/mm 2 , n = 6 mice; p = 0.02) ( Figures 3F-3I ). Finally, we asked whether Chd2 +/À altered caspase-3 mediated interneuron cell death, which peaks around P7 in mice (Southwell et al., 2012) . At P7, we found a decrease in the density of GAD67-GFP+ cells in somatosensory cortex (WT: 781.1 ± 50.78 cells/mm 2 ; Chd2 +/À : 643.3 ± 40.21 cells/mm 2 ; n = 5 mice per genotype; p = 0.04), but the density of cells expressing caspase-3 was not different between genotypes ( Figures 3J-3L ). We conclude that Chd2 haploinsufficiency disrupts cell proliferation and neurogenesis in the developing forebrain, but not developmentally programmed cell death.
Differential Gene Expression in Chd2 +/-Mice As a chromatin modifier, Chd2 likely plays an important role in global transcriptional regulation, but its exact function in brain is unknown (Marfella and Imbalzano, 2007; Tyagi et al., 2016) . Having established that CHD2 is expressed in both the embryonic forebrain and mature neurons, we next sought to identify transcriptional changes resulting from Chd2 haploinsufficiency in an unbiased way. To do this, we performed polyA+ RNA sequencing on tissue micro-dissected from neocortex and MGE of developing embryos at E13.5 as well as hippocampus in adult mice at P45 ( Figure 4A ). We tested for differential expression (DE) across 24,062 genes expressed in our datasets in 9 WT mice and 7 Chd2 +/À littermates. At significance cutoffs Figure S4 . (D) Immunostaining for KI67 (green) in MGE of a WT and Chd2 +/À mouse at E14.5. (E) At 14.5, the density of KI67 + cells was reduced in MGE and cortex of Chd2 +/À mice (n = 3-5 mice per genotype). (F) Immunostaining for NKX2.1 (green) in MGE of a WT and Chd2 +/À mouse at E14.5. (G) At E14.5, the density of NKX2.1 + GABA progenitors was reduced in MGE of Chd2 +/À mice (n = 5-6 mice per genotype). (H) Immunostaining for GAD67-GFP (green) in cortex of a WT and Chd2 +/À mouse at E14.5 (I) At E14.5, the density of GAD67-GFP progenitors was reduced in cortex of Chd2 +/À mice (n = 4-6 mice per genotype). (J) Immunostaining for GAD67-GFP (green) and caspase-3 (magenta) in somatosensory neocortex of a WT and Chd2 +/À mouse at P7. (K and L) At P7, immunostaining analysis revealed a reduction in GAD67-GFP progenitors (K), but the density of cells expressing caspase-3 (CASP-3) was not different between genotypes (n = 5 mice per genotype) (L). corresponding to Benjamini and Hochberg adjusted p value < 0.1, we found 44 (E13.5 MGE), 14 (E13.5 neocortex), and 652 (P45 hippocampus) DE genes in Chd2 +/À mice ( Figure 4B ; Table S2 ). In addition, we further validated expression changes of a randomly selected group of DE genes via qRT-PCR (Figure 4C ). In all three groups, Chd2 was downregulated (E13.5 MGE: 2 ÀDDCt = 0.32, p = 0.04; E13.5 neocortex: 2 ÀDDCt = 0.36, p = 0.04; P45 hippocampus: 2 ÀDDCt = 0.62, p = 0.04) ( Figure 4C ).
Analysis of Gene Ontology (GO) terms revealed brain regionspecific dysregulation in Chd2 +/À mice compared to WT littermates. For this analysis, we expanded the list of DE genes to a significance cutoff of p value < 0.05 for E13.5 datasets, which Table S3 . (E) Plot of Z-score by Àlog 10 of the adjusted p value for human diseases identified by disease ontology. The complete disease ontology is provided in Table S5 . (F) Heatmaps of genes associated with childhood epilepsy, intellectual disability, and autism spectrum disorder that were differentially expressed in E13.5 MGE, E13.5 neocortex, and/or P45 hippocampus. increased sample sizes to 1,416 (E13.5 neocortex) and 622 (E13.5 MGE) DE genes; adjusted p value < 0.1 (p < 0.0045) was used for P45 hippocampus samples. At E13.5, DE genes showed strong enrichment for annotations associated with nervous system development, neuron differentiation, and neurogenesis (Table S3 ). Similar enrichment was observed for DE genes in hippocampus at P45, with numerous additional annotations associated with synapse organization, transcriptional regulation, and behavior ( Figure 4D ; Table S3 ). In particular, we found robust differential expression of transcription factors related to forebrain neurogenesis (e.g., Neurod2, Neurog2, and Sox4), RNA silencers (e.g., Ago2), global regulators of the epigenome (e.g., Ep300 and Smarca4), cell adhesion molecules (e.g., Cdh4 and Pcdh17), and ion channels (e.g., Kcna4 and Cacnb1). However, most striking was the broad range of up-and downregulated genes related to neuronal activity and synaptic plasticity in P45 hippocampus (Table S4 ). Of note, the majority of differentially expressed synaptic molecules are involved in glutamatergic synaptic function (e.g., Grina, Shank2, and Homer1). In agreement with previous reports that chromatin remodeling proteins act as regulators of Wnt signaling pathways (Kwan et al., 2016) , we found downregulation of numerous Wnt pathway genes in Chd2 +/À mice, such as Wnt7a, Wnt7b, Fzd1, Lrp1, Ctnnd2, Apc2, and Apcdd1. However, we noted little overlap in the specific DE genes found in our data compared to prior studies on Chd8 mutation (Durak et al., 2016; Katayama et al., 2016; Gompers et al., 2017; Platt et al., 2017) , suggesting that CHD subfamily members have distinct functional roles in brain.
A number of chromatin remodelers, including Chd2, have been implicated in human neurodevelopmental disorders (Marfella and Imbalzano, 2007; Carvill et al., 2015; Kwan et al., 2016; Tyagi et al., 2016; Mastrototaro et al., 2017; Sokpor et al., 2017) . Therefore, we next asked whether Chd2 +/À altered genes implicated in human disease. Analysis of Disease Ontology (DO) terms identified DE genes for annotations associated with epilepsy and autism spectrum disorders as well as numerous other neurological diseases, such as mental health disorders, congenital disease, and cancer ( Figure 4E ; Table S5 ). In particular, we found 123 DE genes associated with intellectual disability (e.g., Cacna1g, Ctnnd2, and Hexa), childhood epilepsy (e.g., Hdac4, Pcdh19, Reln, and Slc6a1), and/or autism spectrum disorders (e.g., Grin2b, Ktm2a, and Shank2) ( Figure 4F ), some of which are strong candidate ''risk'' genes while others are relatively uncharacterized. Altogether, our results indicate that Chd2 +/À leads to a broad dysregulation of genes involved in neurogenesis, synapse organization, and disease-related pathways.
Chd2 +/-Disrupts Excitatory and Inhibitory Synaptic Function in Hippocampus
The observation that Chd2 +/À drastically alters genes involved in synapse organization led us to investigate whether there is a change in neuronal or synaptic function in Chd2 +/À mice. To do this, we examined electrophysiological properties of CA1 pyramidal neurons at P30-P35 using patch-clamp recordings in acute hippocampal slices ( Figure 5 ). Compared to WT animals, pyramidal neurons from Chd2 +/À mice showed an increase in action potential firing at current injections exceeding 100 pA (genotype: F (1,25) = 2.06; p = 0.164), current step: F (1,16) = 279.22; p < 0.001; genotype by current step interaction: F (1,16) = 4.53; p < 0.001; n = 13 cells from 3 WT mice, n = 14 cells from 4 Chd2 +/À mice; two-way repeated-measures ANOVA) ( Figures 5A and 5B ). Consistent with greater firing capacity in CA1 pyramidal neurons, we also found a significant decrease in spike adaptation at 23 spike threshold in recorded neurons (WT: 1.61 ± 0.13, Chd2 +/À : 1.3 ± 0.07; p = 0.03; Mann Whitney U), but all other intrinsic electrophysiological properties examined were not significantly different between treatment groups ( Figure 5C ; Table S6 ).
Next, we examined miniature excitatory and inhibitory synaptic inputs onto CA1 pyramidal neurons in the presence of 1 mM tetrodotoxin (TTX). Compared to WT littermates, pyramidal neurons in Chd2 +/À mice exhibited a significant increase in miniature excitatory postsynaptic current (mEPSC) amplitudes without a change in event frequency (n = 14 cells from 4 WT mice, n = 16 cells from 4 Chd2 +/À mice; Figures 5D-5F ). This was accompanied by significantly faster decay kinetics in Chd2 +/À mice; 10%-90% rise time was not different between genotypes. (Figures 5G-5I ). In contrast, Chd2 +/À mice exhibited a decrease in miniature inhibitory postsynaptic current (mIPSC) frequency without a change in mIPSC amplitude or event kinetics (n = 20 cells from 3 WT mice, n = 21 cells from 3 Chd2 +/À mice; Figures  5J-5O ). Fewer mIPSCs onto CA1 pyramidal neurons could be explained by a loss of GABAergic synapses or a change in GABA release probability in Chd2 +/À mice (Hirsch et al., 1999) . Therefore, we evaluated evoked IPSC responses to paired stimuli applied to stratum radiatum, a commonly used measure of presynaptic short-term plasticity. However, we did not observe a change in paired-pulse ratio (PPR) of evoked IPSCs between genotypes, suggesting that presynaptic GABA release is unaltered in Chd2 +/À mice ( Figure S5 ). Taken together, our findings indicate that Chd2 +/À alters neuronal excitability and has differential effects on glutamatergic versus GABAergic synaptic transmission in hippocampus.
Chd2 +/-Mice Exhibit Changes in Cortical Rhythmogenesis
A change in the normal balance between excitation and inhibition has the capacity to disrupt naturally occurring oscillations in the brain. Thus, we implanted electroencephalogram (EEG) electrodes into somatosensory neocortex of freely behaving Chd2 +/À mice and WT littermates (n = 5 mice per genotype) and recorded intracranial EEG > 1 week later at P40-P65 ( Figure 6 ). Analyses of the local field potential revealed clear episodes of each frequency band in WT mice and Chd2 +/À littermates, indicating that these rhythms remain intact in the mutants ( Figures 6A  and 6B ). We found that Chd2 +/À mice exhibited a significant increase in the alpha (8-13 Hz) and gamma (30-70 Hz) frequency ranges compared to WT littermates ( Figure 6C ), suggesting that cortical synchrony is increased by Chd2 haploinsufficiency. Notably, elevations in resting alpha or gamma power have been observed in human epilepsies (Willoughby et al., 2003; Vaudano et al., 2017) , autism spectrum disorders (Orekhova et al., 2007; Cornew et al., 2012) , and mouse models featuring deficits in interneuron function (Korotkova et al., 2010; Carlé n et al., 2012; Del Pino et al., 2013; Howard et al., 2014; Cho et al., 2015) . Examination of the mean normalized power spectra for all other frequency ranges revealed no differences between genotypes ( Figure 6C ). Further analysis revealed differences in cross-cortical coherence (a measure of phase and amplitude synchrony between hemispheres) in delta, theta, and gamma frequency ranges ( Figure 6D ). Next, we performed 24 hr/7 day EEG monitoring to test whether Chd2 +/À mice develop spontaneous electrographic seizures. In 7 days of continuous monitoring at P40-P65, we did not observe any overt convulsive seizures in WT or Chd2 +/À mice (n = 6 mice per genotype). Altogether, these findings indicate that Chd2 haploinsufficiency leads to a dysregulation of neural oscillations and synchrony in cortex.
Chd2 +/-Disrupts Long-Term Memory Memory requires changes in neuronal gene expression that are coordinated, at least in part, by epigenetic mechanisms and chromatin regulation (Levenson and Sweatt, 2005; Vogel-Ciernia et al., 2013; Mews et al., 2017) . To assess longterm memory in Chd2 +/À mice, we used the well-characterized object location and recognition memory paradigms (Vogel-Ciernia and Wood, 2014) (Figure 7; Figures S6A and S6B) . During a 10 min habituation phase in the open field arena, the total distance traveled was not different between groups, but Chd2 +/À mice spent more time in the center region of the arena, as compared to WT littermates (Figures S6C-S6E;  Table S7 ). In the object location task, WT mice exhibited increased exploration of the object that had been moved (Figures 7A-7C ). In contrast, Chd2 +/À mice explored both objects equally ( Figures 7A-7C ) and displayed a significantly lower discrimination index compared to WT controls (Figures 7B and 7C) . Similarly, in the object recognition task, WT mice exhibited increased exploration of the novel object ( Figures  7D-7F ), but Chd2 +/À mice explored both objects equally (Figures 7D-7F ) and displayed a significantly lower discrimination index compared to WT controls ( Figures 7E and 7F ). There was no difference in the time spent exploring the objects ( Figures  S6F and S6G ), suggesting that the poor performance of Chd2 +/À mice was not due to disinterest in the objects and that locomotor activity during training and test phases was comparable between groups ( Figure S6E ). Chd2-conditional mutant mice with Chd2 haploinsufficiency only in inhibitory interneurons (Nkx2.1-Cre; Chd2 loxP/+ ; Ai14-tdTomato mice) showed similar impairments in interneuron density and memory behaviors ( Figure S7 ). We conclude that Chd2 +/À mice exhibit severe deficits in long-term spatial and recognition memory, and this is due, at least in part, to a reduction in the number of cortical interneurons.
MGE Transplantation Rescues Spatial Memory
Problems in Chd2 +/-Mice In hippocampus, deficits in interneuron number or function have been implicated in a wide range of cognitive disorders, such as Alzheimer's disease (Satoh et al., 1991) , intellectual disability (Opperman et al., 2017) , and epilepsy (de Lanerolle et al., 1989) . With this in mind, we next asked whether transplantation of inhibitory interneurons is sufficient to ''rescue'' memory deficits observed in Chd2 +/À animals. To do this, MGE progenitors were obtained from E13.5 b-actin:GFP donor mice, and 5 3 10 4 cells were injected bilaterally into hippocampus of neonatal recipients at P5 ( Figure 8A ). We performed polyA+ RNA sequencing and DE analysis between MGE and neocortex micro-dissected from E13.5 embryos to confirm that the grafted cells expressed genes highly enriched in MGE-derived progenitors (Olig2, Dlx5, Lhx6, Pou3f4, and Gad1) ( Figure 8B ; Table S8 ). By 45 days after transplant (DAT), MGE-GFP cells migrated away from the injection and were dispersed throughout hippocampal subfields (n = 3 mice per genotype) ( Figure 8C; Figures S8A and S8B ). GFP-labeled cells expressed the interneuron markers PV (WT: 18% ± 4%; Chd2 +/À : 24% ± 6%) and SST (WT: 35% ± 6%; Chd2 +/À : 28% ± 2%) but did not express VIP (<1% both genotypes) (Figure 8D) . No differences in marker expression were detected between genotypes ( Figure S8C ). Finally, we assessed the effect of MGE transplantation on long-term memory. Replication with a second, independent cohort of WT and Chd2 +/À mice showed that Chd2 +/À mutants had deficits in both object location and recognition memory tasks ( Figures 8E and 8F ). Chd2 +/À mice that received MGE grafts exhibited improvement in the novel object location task, but not the object recognition assay; MGE transplantation had no effect on memory in WT animals. These findings suggest that increasing the number of inhibitory interneurons is sufficient to restore deficits in long-term spatial memory of Chd2 +/À mice, but recognition memory remains impaired.
DISCUSSION
Our results provide the first comprehensive molecular and physiological analysis of Chd2 haploinsufficiency. Using a new mouse model of Chd2 mutation, we found alterations in neural progenitor proliferation in the embryo as well as defects in synaptic transmission, cortical synchrony, and hippocampal-dependent memory behavior in adult mice. In agreement with these findings, transcriptome analysis revealed broad changes in the expression of genes involved in chromatin regulation, neurogenesis, and synaptic transmission. Transplantation of MGE-derived interneurons rescued deficits in interneuron number and hippocampal-dependent spatial memory. While Chd2 +/À mice exhibited changes in excitation-inhibition activity at the synaptic and network levels, we did not observe overt spontaneous seizures. However, many individuals with CHD2 haploinsufficiency also do not have epilepsy, and CHD2 mutations have been identified in patients with autism and intellectual disability without seizures (Hamdan et al., 2014) . Overall, these observations demonstrate that Chd2 +/À mice reproduce many, but not all, of the key behavioral phenotypes observed in humans with Chd2 mutations. Careful phenotyping of additional patients will help better define the phenotypic spectrum of this disorder in human.
An emerging literature on chromatin biology is revealing that genes encoding CHD proteins are critical regulators of brain development, from cell proliferation to differentiation (Marfella et al., 2006 (Marfella et al., , 2008 Marfella and Imbalzano, 2007; Shen et al., 2015; Durak et al., 2016; Katayama et al., 2016; Kwan et al., 2016; Tyagi et al., 2016; Mastrototaro et al., 2017; Sokpor et al., 2017; Gompers et al., 2017; Platt et al., 2017; Meganathan et al., 2017) . Whereas most studies have focused on cell signaling pathways and/or behavioral phenotypes, our results demonstrate a potential link between chromatin regulation and behavior via alterations in synaptic transmission and cortical network synchrony. Though CHD2 is located in cell nuclei, we found that Chd2 mutations perturb neural circuit function in at least two distinct ways in the mature brain depending on the system. In glutamatergic circuits, which have a prominent role in hippocampal-dependent learning and memory, we observed transcriptional changes related to pre-and post-synaptic domains that lead to an increase in glutamatergic transmission and faster event kinetics. In contrast, reduced progenitor proliferation predominates in GABAergic circuits, and this leads to fewer inhibitory interneurons and a reduction in synaptic inhibition in hippocampus. The balance of excitatory-inhibitory synaptic interactions is essential for the formation of neural oscillations (Atallah and Scanziani, 2009 ) and memory (Lim and Goldman, 2013) , deficits we observed in Chd2 +/À mice.
Early insight into the function of CHD2 in brain indicated expression of repressor element 1-silencing transcription factor (REST), a master regulator of neuronal development, was positively correlated with CHD2 (Shen et al., 2015) , which may lead to alterations in radial glia self-renewal and neurogenesis when disrupted. Our RNA sequencing analysis did not confirm downregulation of REST in any brain region examined. This may be related to differences between in utero knockdown via Chd2 shRNA delivery to embryonic ventricles and transgenic mutation; transcriptional changes in REST following in utero knockdown of Chd8 also could not be replicated by germline mutation (Durak et al., 2016; Katayama et al., 2016; Gompers et al., 2017; Platt et al., 2017) . One of the main differences between Chd2 +/À and other mouse models of Chd mutation (e.g., Chd8 +/À ) is that Chd2 +/À mice have a severe interneuron deficit whereas no such deficit has been reported in any of the mouse models of Chd8 +/À (Durak et al., 2016; Katayama et al., 2016; Gompers et al., 2017; Platt et al., 2017) . Indeed, a recent report suggests that Chd2 may co-associate with Nkx2.1 at cis-regulatory elements to regulate gene expression programs in presumptive interneurons derived from human embryonic stem cells (Meganathan et al., 2017) . We found evidence of altered neurogenesis in Chd2 +/À mice, notably a reduction in precursor pools of both excitatory and inhibitory neurons in the embryonic forebrain. Nevertheless, a clear disruption of cortical cytoarchitecture was not apparent in mutant animals, consistent with the absence of structural brain abnormalities among many people with CHD2 mutations (Ché nier et al., 2014) . It is possible that Chd2 also plays a role in the development of non-neuronal cell types, such as oligodendrocytes or astrocytes. Our experiments primarily focused on analysis of neural progenitors, because we did not observe co-localization of CHD2 in GFAP+ cells or a change in OLIG2+ cell densities in Chd2 +/mice. A detailed and direct analysis of individual neuronal and glial cell types should clarify the developmental source or molecular mechanisms driving Chd2-related pathology. Nevertheless, our findings suggest that cell-type specification and migration of neural progenitors into the cortex remains largely intact in Chd2 +/mice.
Hundreds of rare gene mutations are now associated with neurodevelopmental disorders, many of which have devastating behavioral consequences that cannot be managed with available treatment options. Although discovery of new diseaseassociated gene mutations has been expanding rapidly, a major challenge in the field is to identify mechanisms underlying each of these rare disorders so that new, disease-specific therapies can be developed. Our results suggest interventions targeting cell proliferation and/or synaptic signaling may be particularly promising therapeutic candidates in Chd2 haploinsufficiency. Given that DO analysis revealed 16 DE genes associated with obesity and the strong link between altered metabolism and seizures (Scharfman, 2015) , metabolic pathways may be a promising disease target as well. Indeed, some patients with CHD2 mutation found improvement with ketogenic diet (Chd2 Support and Research Group; https://www.facebook.com/ groups/1462485137354985/), and there is evidence of improved memory performance with this treatment in aging mice (Newman et al., 2017) . While further studies of the neuroanatomical and physiological changes associated with Chd2 mutations are necessary before precise therapies can be designed and translated to the clinic, our results are an important step toward understanding how mutations in Chd2 impact brain development and function.
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: 
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Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Robert F. Hunt (robert.hunt@uci.edu) .
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Mice
Mice were maintained in standard housing conditions on a 12h light/dark cycle with food and water provided ad libitum. All protocols and procedures followed the guidelines of the University Laboratory Animal Resources at the University of California, Irvine and adhered to National Institutes of Health Guidelines for the Care and Use of Laboratory Animals. To generate Chd2-flox mice (i.e., Chd2 tm1c(EUCOMM)Hmgu mice), we obtained sperm with tm1c conditional allele from The Centre for Phenogenomics and re-derived the transgenic line on a C57BL/6J background (Jackson Laboratories cat. no. 000664) at the UCI Transgenic Mouse Facility. A full description of the targeting of Chd2 can be found at International Mouse Phenotyping Consortium (https://www. mousephenotype.org/data/genes/MGI:2448567). Chd2-flox mice were then crossed for three generations to WT C57BL/6J mice and the offspring of the third generation was crossed to an ACTB-Cre line (Jackson Laboratories cat. no. 019099) to generate Chd2 +/À mice. In some experiments, Chd2-flox mice were mated with a Nkx2.1-Cre (Jackson Laboratories cat. no. 008661), an Ai14 tdTomato reporter (Jackson Laboratories cat. no. 007908) or a hemizygous glutamic acid decarboxylase -enhanced green fluorescence protein (GAD67-GFP) knockin line maintained on a CD-1 background (Tamamaki et al., 2003) . To obtain embryos for MGE transplantation, male b-actin:GFP mice (Jackson Laboratories cat. no. 006567) were crossed to CD-1 females (Charles River, cat no. 022). Experiments were performed on male and female littermates between E14.5 and P75.
METHOD DETAILS
Experimental Design
Experiments were performed on male and female littermates between E14.5 and P75. Animals were randomly allocated to experimental groups, and the experimenter was blinded to genotype of the animals until the experiment was complete. No data or animals were excluded from analysis. Memory behavior assays were replicated using a separate, independent cohort of WT and Chd2 +/À littermates. No other replication studies were performed.
Western Blot
Western blot was performed on P30 mice as previously described (Luijsterburg et al., 2016) . Nuclear protein extracts from whole brain were prepared by homogenizing the tissue in subcellular fractionation buffer (20 mM HEPES (pH7.4), 74.55 mM KCl, 95.21 mM MgCl2, 292.24 mM EDTA, 380.35 mM EGTA, 1 mM DTT and 1x Protease inhibitor cocktail). Proteins were separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to PVDF membranes. Protein expression was analyzed by immunoblotting. Primary antibodies and dilutions are provided in the Key Resources table. Secondary antibodies were IRDye 800CW (LI-COR) and CF770 (Biotium). Gels were imaged and quantified using a LI-COR Odyssey infrared imaging scanning system.
Immunostaining
Mice were transcardially perfused with 4% paraformaldehyde (PFA) and free-floating vibratome sections (50 mm) were processed using standard immunostaining procedures (Hunt et al., 2013) . For E14.5 embryos, brains were dissected and drop-fixed overnight in 4% PFA. For PAX6, KI67, and TBR2 staining, sections were pretreated with an antigen unmasking solution (10mM Sodium Citrate, pH 6.0) for 60 min at room temperature. All antibodies have been previously used for immunostaining analysis in brain. Primary antibodies and dilutions are provided in the Key Resources table. Secondary antibodies were: Alexa 488, Alexa 546, Alexa 594 and Alexa 647 (Invitrogen). Sections were then mounted on charged slides (Superfrost plus; Fisher Scientific) with Vectashield that contained DAPI or Aqua Mount. Images were obtained with a Leica DM6 epifluorescence microscope or an Olympus FV3000 laser-scanning confocal microscope. Brightness and contrast were adjusted manually using Adobe Photoshop; z stacks were generated using Olympus, Leica or Helicon Focus 6 software.
Cell Quantification
Fluorescently labeled sections (50 mm) were imaged using a Leica DM6 microscope with a x10 or x20 objective or Olympus FV3000 confocal microscope with a x20 or x40 objective and counted using ImageJ, as described previously (Hunt et al., 2013) . All cells that expressed a subtype maker were counted in every sixth coronal section (that is, 300 mm apart). Four to six sections were analyzed per animal and the values averaged to obtain a mean cell density (cells / mm 2 ). Intensity measurements were analyzed within regions of interest and a range of threshold limit was applied using ImageJ according to a previous protocol (Jensen, 2013) .
Timm's Staining
Animals were perfused transcardially with 0.37% sodium sulfide solution in 0.1 M NaHPO4, followed by 4% PFA and stored overnight in 4% PFA solution. Brains were then sectioned at 50 mm on a vibratome and every sixth section mounted on charged slides (Superfrost Plus; Fisher Scientific). Sections were dried overnight and treated according to previous protocols using Timm's stain to reveal mossy fibers and Nissl counterstained with cresyl violet to visualize cell bodies (Tauck and Nadler, 1985; Hunt et al., 2009) . To semiquantitatively assess the presence or absence of mossy fiber sprouting into the inner molecular layer of the dentate gyrus, Timm scores from 0 (little to no sprouting) to 3 (robust mossy fiber sprouting) (Tauck and Nadler, 1985; Hunt et al., 2009 ) were assigned to six randomly chosen sections from the dorsal portion of the hippocampus and averaged for each animal. Images were taken with a Leica MZ10F stereoscope.
RNA Sequencing
Total RNA was isolated from freshly dissected tissue using the Direct-zol RNAMiniPrep Plus kit (Zymo Research) according to the manufacturer instructions. RNA quantity and quality were then determined for each sample using NanoDrop (ThermoFisher), Qubit RNA BR Assay Kit (ThermoFisher), and a TapeStation (Agilent). Samples were then converted to cDNA using the NEBNext Ultra RNA Library Preparation Kit (NEB) with poly(A) selection. Paired-end sequencing was performed on the Illumina HiSeq 4000 platform by GENEWIZ Next Generation Sequencing facility (South Plainfield, NJ). Quality of the raw sequencing reads was accessed using FASTQC and adaptors were trimmed with Trimmomatic. Reads for each library (32.7 ± 4.6 million per replicate, n = 18 replicates) were then aligned using TopHat2 (version 2.1.1) and the mouse genome index mm10 generated from iGenome UCSC mm10 FASTQ genome sequence.
Differential Expression Analysis
Quantification and differential expression of the annotated mouse genes were performed using DESeq2 as previously described (Love et al., 2014) using three biological replicates for each dataset. Differences were considered statistically significant with Benjamini and Hochberg (BH) adjusted p value < 0.10 and p values < 0.05. GO analysis and functional classification were performed separately on up-or downregulated genes using the R package goseq (Young et al., 2010) , with corrected gene length and expressed genes as the background test set. Significance was set at Benjamini and Hochberg adjusted p value < 0.1 or p value < 0.05. DO analysis of functional enrichment based on human diseases in the DisGeNET database (http://www.disgenet.org/) was performed separately on up-or downregulated genes using the R package DOSE (Yu et al., 2015) and expressed genes as the background test set. Heatmaps and bubble plot were generated with the R packages pheatmap and GOplot. For disease gene plots in Figure 4F , risk genes for epilepsy, intellectual disability and/or autism were determined based on the following databases: SFARI Human Gene Module (https://gene.sfari.org/database/human-gene), Citizens United Against Epilepsy (CURE) Foundation Epilepsy Genetics Initiative (https://www.cureepilepsy.org/egi), DECIPHER v9.17 (https://decipher.sanger.ac.uk) and ID Gene Database Project (http://gfuncpathdb.ucdenver.edu/iddrc/iddrc/home.php). We found a significant disruption in Tmem163 of Chd2 +/À mice (Table S2) , which is likely the result of Cre insertion into intron 4 of Tmem163 in the ACTB-Cre line (Cain-Hom et al., 2017) . Since we analyzed three female and three male samples by chance for the comparison of WT and Chd2 +/À MGE, we also found several sex-specific genes with significant and large changes (Table S2) . Instruments) . For current-clamp experiments, cells were held at À70 mV, and electrophysiological properties were measured in response to a series of long (1000 ms) hyperpolarizing and depolarizing current-injections (10 pA steps; range: À80 pA to 160 pA). Voltage-clamp recordings were examined at a holding potential of À70 mV. Glutamatergic currents were measured in the presence of 30uM bicuculine, GABAergic currents were measured in the presence of 1mM kynurenic acid and 1uM TTX was added to the bath to isolate miniature PSCs. A concentric bipolar stimulating electrode made of platinum-iridium wire (125 mm diameter; FHC) was used to apply paired stimuli to CA1 stratum radiatum (100 ms duration, 100ms interstimulus interval). Stimulus intensity was set at 1.5 x threshold, where threshold was defined as the stimulus required for evoking an IPSC in 50% of the trials. Ten consecutive responses were obtained at 0.1 Hz, averaged and the ratio of the amplitude of the second evoked IPSC to the first (eIPSC2/eIPSC1) was calculated to obtain the paired-pulse ratio (PPR). Series resistance was uncompensated and monitored throughout the recordings. Data were only used for analysis if the series resistance remained < 20 MU and changed by % 20% during the recordings. Recordings were not corrected for a liquid junction potential. Resting membrane potentials were measured immediately after breakthrough by temporarily removing the voltage clamp and monitoring voltage. Data analysis was performed using pClamp 10.7, MiniAnalysis 6.0.7 (Synaptosoft), Microsoft excel or Sigmaplot 13 programs. A 2 min sample recording per cell was used for measuring event frequency, amplitude, 10%-90% rise time, and decay time constant. Events characterized by a typical fast rising phase and exponential decay phase were manually detected using MiniAnalysis. The threshold for event detection was currents with amplitudes greater than three times the root mean square (RMS) noise level.
Electroencephalography (EEG)
Male Chd2 +/À mice and age-matched male WT littermates were housed together before and after EEG surgeries. Local field potential recordings were obtained at 2kHz using an EEG monitoring system (Pinnacle Technologies) as previously described (Hunt et al., 2013; Khoshkhoo et al., 2017) . Briefly, mice were anesthetized with ketamine and xylazine (10 mg/kg and 1 mg/kg i.p.), and sterile, stainless steel screw recording electrodes were placed epidurally through burr holes in the skull using surface head-mount EEG hardware (Pinnacle Technologies). The EEG recording electrodes were implanted at (in millimeters relative to the bregma): À1.25AP, ± 1.5ML; reference electrode was implanted at À5.0 AP, 0 ML (in cerebellum), and a ground electrode was implanted at À3.5 AP, À3.0 ML. Electrodes were cemented in place with a fast-acting adhesive and dental acrylic. Two wires were laid on the shoulder muscles for electromyographic (EMG) recording. Animals were allowed to recover for at least 7 days before experiments were initiated and then monitored for 7-10 days (24 h/day). EEG recordings for each mouse were visualized in 1 hr time windows and carefully inspected for any abnormal electrographic signals or seizures. This process was repeated twice for each animal. All analyses were performed using custom-written and built-in MATLAB (MathWorks) functions. To generate EEG power plots, total EEG power for each frequency interval was calculated in 10 min bins using the MATLAB function bandpower and averaged over 1 hr intervals. Then, the output was normalized by the total area under the curve (for frequencies < 100 Hz, excluding 59-61 Hz) for each mouse. To analyze changes in baseline power 60 hr of continuous EEG recording, hours 12 through 72, was included for each mouse in order reduce the effect of arousal and environmental noise in our analysis. Two-way ANOVA was used to assess the effect of genotype, frequency, and genotype-frequency on baseline EEG power followed by a Tukey-Kramer multiple comparisons test to compare EEG power for each frequency band. To assess inter-hemispheric synchronization in each frequency interval, coherence between the EEG signals from the two hemispheres was calculated using the MATLAB function mscohere in 10 min bins, and averaged over 1 hr. A total of 60 hr of continuous EEG recording was included in this analysis for each mouse. Two-way ANOVA was used to assess the effect of genotype, frequency, and genotype-frequency on inter-hemispheric coherence followed by a Tukey-Kramer multiple comparisons test to compare inter-hemispheric coherence in mutant and WT mice for each frequency band.
Object Location and Recognition Memory Assays
Each object location task consisted of a habituation phase, training phase, and testing phase and were performed according to a previous protocol (Vogel-Ciernia et al., 2013; Vogel-Ciernia and Wood, 2014) . Mice were handled for 2-5 min on 5 consecutive days before testing. On day 1, animals were habituated individually to the open field arena. Mice were placed in the center of a 40 cm 3 40 cm 3 35 cm open field arena with a vertical marking strip for 10 min under dim overhead lighting conditions (45 lux). For the training session (day 2), two identical objects were placed in the open field, 1 cm from the back wall and mice were placed in the center of the opposite wall. Animals were allowed to explore each object for 10 min. The arena and objects were cleaned with 70% (v/v) EtOH (OLM) or 1% acetic acid (ORM) between trials. A retention test was performed 24 hr after the training session (day 3). For OLM, one object was placed in a different location. For ORM, one object was exchanged for a new object that was different in size, shape, and texture. The objects used were Falcon 50mL conical centrifuge Tubes (Fisher, Cat no. 14-432-22) filled with beach sand, 3D printed cube and a 75mL glass flask. For detailed description of the experimental setups, schematics are shown in Figures  S6A,B and S7C,E. All behavioral assays were conducted between 2pm and 6pm during the light phase of the light/dark cycle (lights off at 8pm; lights on at 8am). Mouse identities were coded, and all behaviors were performed using a video tracking system and analyzed using ANY-maze software by investigators who were blind to the genotype and treatment of the animals. A mouse was scored as exploring an object when its head was oriented toward the object within a distance of 1 cm or when the nose was touching the object. The relative exploration time was recorded and expressed by a discrimination index (DI = [t novel -t familiar ]/[ t novel + t familiar ] 3 100) where t represents time. Mean exploration times were calculated and the discrimination indexes between treatment groups were compared. To diminish bias, control and mutant littermates were evaluated on the same day in the same arena, and the location of the novel object was counterbalanced across experiments and groups.
MGE Transplantation
Ventricular and subventricular layers of the MGE were harvested from E13.5 GFP+ embryos. The time point at which the sperm plug was detected was considered E0.5. Embryonic MGE explants were dissected in Leibovitz L-15 medium, mechanically dissociated by repeated pipetting and concentrated by centrifugation (3 min at 1,000 g). Concentrated cell suspensions ($10 3 cells nl À1 ) were front loaded into beveled glass micropipettes ($50-mm tip diameter, Wiretol 5 ml, Drummond Scientific) and bilaterally injected (5 3 10 4 cells per injection) into dorsal hippocampus of WT or Chd2 +/À littermates at P5 as described previously (Hunt et al., 2013; Vogt et al., 2014) .
QUANTIFICATION AND STATISTICAL ANALYSIS
Samples were randomly collected across litters and processed blind to genotype. All analyses were performed with SYSTAT 13.1 software and assessed for normality (Shapiro-Wilk) and variance (Brown-Forsythe). Mossy fiber sprouting scores and intrinsic electrophysiological properties were assessed by nonparametric Mann-Whitney U test on ranks. All other data were compared by two-tailed t test, one-way ANOVA for multiple comparisons or by two-way repeated-measures ANOVA. A Tukey's post hoc test was performed when appropriate. Sample sizes for behavior assays were determined by power analyses using 20% as a value for b (1 -b = power or 80%), 0.05 as a value for a and an expected 30% difference between groups; post hoc power for each behavior assay is indicated in Table S7 . No statistical methods were used to predetermine sample size in other experiments. Sample sizes can be found within results and/or figure legends, and individual data points are shown for each quantification. For slice electrophysiology studies, experimental data were averaged across neurons (i.e., n = neurons). In all other studies, experimental data were averaged across animals (i.e., n = mice). Data are expressed as mean ± standard error (SEM) and significance was set at p < 0.05. For differential gene expression analysis, significance was set at FDR < 0.10 and p < 0.05.
DATA AND SOFTWARE AVAILABILITY
All RNA-seq data are available in Tables S1 and S2; raw counts from RNA-sequencing are available on the Gene Expression Omnibus, GEO: GSE112196. Data that support the findings of this study are available from the corresponding authors upon reasonable request.
